Specialty Pharmacy

Tivozanib (Fotivda) improved progression-free survival and reduced risk of death in patients with highly refractory advanced or metastatic disease.

Hispanic adults in the US who are infected with human immunodeficiency virus face a greater risk of cancers caused by human papillomavirus (HPV) than Hispanics in the general public.

Stopping treatment with fingolimod (Gilenya) can cause the disease to become much worse than before the medicine was started or while it was being taken, FDA officials warned.

Emapalumab (Gamifant) is the first treatment specifically approved for primary hemophagocytic lymphohistiocytosis, a rare and life-threatening immune disease.

Study identifies potential biomarkers that could provide a quicker path to diagnosis of amyotrophic lateral sclerosis.

Top news of the day from across the health care landscape.

New study finds that ocrelizumab (Ocrevus) has the capability to reduce risk of upper extremity disability progression in patients with primary progressive multiple sclerosis (PPMS).

Lasmiditan’s mechanism is distinct from other therapies and, if approved, represents significant innovation in the acute treatment of migraine.

A new study shows high prevalence of atopic dermatitis among adults, illustrating the need for more available treatment options.

Top news of the day from across the health care landscape.

The FDA expanded the label for eltrombopag (Promacta) to now include indication for adults and pediatric patients 2 years and older with severe aplastic anemia in combination with standard immunosuppressive therapy.

The FDA has expanded the approved use of Seattle Genetics’ Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

The statement is intended to serve as a discussion guide for the risk factors, diagnosis, treatment and prevention of the disease.

NYU Langone Health discusses the challenges and benefits involved in starting or expanding a health system’s specialty pharmacy.

Study evaluates the association between body mass index in late adolescence and the incidence of pancreatic cancer in adulthood.

The FDA granted the designation to brentuximab vedotin (Adcetris) for this indication in combination with cyclophosphamide, doxorubicin, and prednisone.

Top news of the day from across the health care landscape.

Direct-acting antivirals are a costly but highly-effective class of drugs for the treatment of hepatitis C that can cure most cases.

Emgality (Galcanezumab-gnlm) is a self-administered once monthly subcutaneous injection and the third in its class for the preventative treatment of migraine in adults.

The new formulary will allow health plans to cover lower list price products, such as new authorized alternatives to brand-name medications.

Top news of the day from across the health care landscape.

One hundred percent of patients with hepatitis C virus genotypes 1, 2, 4, 5 and 6 achieved a sustained virologic response at 12 weeks post treatment with 8 weeks of glecaprevir/pibrentasvir treatment.

The FDA accepted a supplemental New Drug Application for olaparib’s (Lynparza) new indication for first-line maintenance treatment of advanced ovarian cancer.

Top news of the day from across the health care landscape

Sofosbuvir, velpatasvir, and voxilaprevir successful in patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence to direct-acting antiviral drug regimens.